Search Results - "Jacob, Stephan"

Léčba inzulinem u diabetu 2. typu - co nejdříve?...Jan Šoupal, Martin Prázný.

Authors: Müssig, Karsten Jacob, Stephan

Source: Medicina po Promoci. 2016, Vol. 17 Issue 4, p368-371. 4p.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care.

Authors: Jacob, Stephan Krentz, Andrew J. Deanfield, John et al.

Source: Drugs. Aug2021, Vol. 81 Issue 12, p1373-1379. 7p.

Effects of Chronic Antagonism of Endocannabinoid-1 Receptors on Glucose Tolerance and Insulin Action in Skeletal Muscles of Lean and Obese Zucker Rats.

Authors: Lindborg, Katherine A. Jacob, Stephan Henriksen, Erik J.

Source: CardioRenal Medicine. 2011, Vol. 1 Issue 1, p31-44. 14p.

Cardiovascular outcome trials in obesity: A review.

Authors: Wilding, John P.H. Jacob, Stephan

Source: Obesity Reviews. Jan2021, Vol. 22 Issue 1, p1-11. 11p.

Beta-blocking agents in patients with insulin resistance: effects of vasodilating beta-blockers.

Authors: JACOB, STEPHAN BALLETSHOFER, BERND HENRIKSEN, ERIK J. et al.

Source: Blood Pressure. Dec99, Vol. 8 Issue 5, p261-268. 8p. 4 Diagrams, 1 Chart.

Global cardiometabolic alliance: A clinical and research initiative addressing the 21st century pandemic of insulin resistance‐associated disease.

Authors: Eckel, Robert H. Krentz, Andrew J. Jacob, Stephan et al.

Source: Diabetes, Obesity & Metabolism. Nov2025, Vol. 27 Issue 11, p6101-6104. 4p.

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial.

Authors: Tack, Cees J. Jacob, Stephan Desouza, Cyrus et al.

Source: Diabetes, Obesity & Metabolism. Nov2019, Vol. 21 Issue 11, p2450-2458. 9p.

Corrigendum to "Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis" [Atherosclerosis, Vol 396, (September 2024), 118528].

Authors: Krentz, Andrew Jacob, Stephan Heiss, Christian et al.

Source: Atherosclerosis (00219150). Nov2024, Vol. 398, pN.PAG-N.PAG. 1p.

Rising to the challenge of cardio-renal-metabolic disease in the 21st century: Translating evidence into best clinical practice to prevent and manage atherosclerosis.

Authors: Krentz, Andrew Jacob, Stephan Heiss, Christian et al.

Source: Atherosclerosis (00219150). Sep2024, Vol. 396, pN.PAG-N.PAG. 1p.

Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus

Authors: Winkler, Karl Jacob, Stephan Müller-Schewe, Tina et al.

Source: Atherosclerosis (00219150). Jan2012, Vol. 220 Issue 1, p189-193. 5p.

Metabolic Properties of Vasodilating β Blockers: Management Considerations for Hypertensive Diabetic Patients and Patients With the Metabolic Syndrome.

Authors: Jacob, Stephan Henriksen, Erik J.

Source: Journal of Clinical Hypertension. Dec2004, Vol. 6 Issue 12, p690-698. 9p. 1 Chart, 2 Graphs.

Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects.

Authors: Jacob, Stephan Machann, Jurgen Rett, Kristian et al.

Source: Diabetes. May99, Vol. 48 Issue 5, p1113-1119. 7p. 3 Diagrams, 3 Charts.

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.

Authors: Schnell, Oliver Barnard-Kelly, Katharine Battelino, Tadej et al.

Source: Cardiovascular Diabetology. 3/19/2024, Vol. 23 Issue 1, p1-17. 17p.

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.

Authors: Wharton, Sean Lingvay, Ildiko Bogdanski, Pawel et al.

Source: New England Journal of Medicine. 9/18/2025, Vol. 393 Issue 11, p1077-1087. 11p.

53-OR: Efficacy of Efpeglenatide in Patients with Obesity and Prediabetes: A Subanalysis of the BALANCE 205 Study.

Authors: PRATLEY, RICHARD E. JACOB, STEPHAN KANG, JAHOON et al.

Source: Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.

1001-P: Effects of Efpeglenatide on Body Weight, BMI, and Waist Circumference in Patients With Obesity Without Diabetes Stratified by Baseline Characteristics: A Subanalysis of BALANCE 205.

Authors: PRATLEY, RICHARD E. JACOB, STEPHAN KANG, JAHOON et al.

Source: Diabetes. 2019 Supplement, Vol. 68, pN.PAG-N.PAG. 1p.